Molly Burich, MS, associate director of public policy: biosimilars, pipeline, and reimbursement at Boehringer Ingelheim, discusses current FDA guidance on the naming and labeling of biosimilar treatments.
Transcript:
What impact does current guidance on naming and labeling have on prescribing biosimilars?
I think we’re very thankful that the FDA has released draft guidance on labeling and finalized its naming guidance. These are both important steps. The labels and the names in many ways are how patients and physicians know the product and learn the product, and for physicians how they understand the clinical data behind it.
In terms of labeling, we support that the label should look very similar to the reference product. After all, these are biosimilars to the reference product, so we believe that those labels should look very similar and are pleased with the direction the FDA seems to be taking in labeling. As it pertains to naming, the FDA did end up finalizing the use of a four-digit suffix that is devoid of meaning. I think this is a little bit challenging and this result was not what a lot of stakeholders, including some biosimilar manufacturers, wanted to see. I think we would have preferred that a suffix, if it’s needed, has to be meaningful so that doctors and patients, if needed, can remember it and it’s attributed to the manufacturer.
Unfortunately, that isn’t the way the agency went. So, that’s another opportunity for education to make sure that physicians know our suffix, know that it’s devoid of meaning as much as they can remember it, and that patients certainly understand that while there is a suffix that differentiates it, it doesn’t mean the product is any less safe or efficacious.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.